Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Revenue of Innate Pharma S.A. (IPHA)
Revenue in 2023 (TTM): $51.9 M
According to Innate Pharma S.A.'s latest financial reports the company's current revenue (TTM) is $51.9 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Innate Pharma S.A.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $51.9 M | $-4,121,000 | $-17,316,000 | $-17,299,000 | $-7,570,000 |
| 2022 | $49.64 M | $-2,024,000 | $33.75 M | $-57,972,000 | $-99,103,000 |
| 2021 | $12.11 M | $-34,892,000 | $-36,885,000 | $-45,478,000 | $-59,136,000 |
| 2020 | $56.83 M | $53.79 M | $43.11 M | $-63,984,000 | $-70,747,000 |
| 2019 | $68.97 M | $23.82 M | $-8,883,000 | $-20,759,000 | $-20,965,000 |
| 2018 | $79.89 M | $10.34 M | $12.36 M | $2.72 M | $3.05 M |
| 2017 | $32.63 M | $-34,369,000 | $-35,649,000 | $-48,016,000 | $-48,385,000 |
| 2016 | $56.16 M | $7.53 M | $11.64 M | $12.94 M | $12.64 M |
| 2015 | $17.91 M | $-12,000,000 | $-8,090,000 | $-6,706,000 | $-6,706,000 |
| 2014 | $907 K | $-11,180,000 | $-17,848,000 | $-19,647,000 | $-19,647,000 |
| 2013 | $12.47 M | $4.89 M | $-2,207,000 | $-2,892,000 | $-2,892,000 |
| 2012 | $10.38 M | $3.51 M | $-2,866,000 | $-3,199,000 | $-3,199,000 |
| 2011 | $11.74 M | $10.1 M | $-5,540,000 | $-6,980,000 | $-6,980,000 |
| 2010 | $4.32 M | $893 K | $-12,590,000 | $-13,658,000 | $-13,658,000 |
| 2009 | $7.72 M | $4.37 M | $-14,466,000 | $-14,626,000 | $-14,626,000 |
| 2008 | $12.92 M | $10.37 M | $-10,467,000 | $-9,852,000 | $-9,852,000 |
| 2007 | $14.29 M | $11.52 M | $-8,504,000 | $-8,918,000 | $-8,918,000 |
| 2006 | $6.2 M | $3.99 M | $-5,693,000 | $-6,042,000 | $-6,042,000 |
| 2005 | $1.3 M | $356 K | $-5,828,000 | $-6,129,000 | $-6,129,000 |